Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Feb 1

PMID 29382047

Citations 11

Authors

William Berry

Joanne Lundy

Daniel Croagh

Brendan J Jenkins

Affiliations

Soon will be listed here.

Abstract

Advanced pancreatic cancer (PC) is an aggressive malignancy with few effective therapeutic options. While the evolution of precision medicine in recent decades has changed the treatment landscape in many cancers, at present no targeted therapies are used in the routine management of PC. Only a minority of patients with PC present with surgically resectable disease, and in the remainder obtaining high quality biopsy material for both diagnosis and molecular testing can prove challenging. Endoscopic ultrasound-guided fine needle aspiration (EUS FNA) is a widely used diagnostic procedure in PC, and allows tumour sampling in patients with both early and late stage disease. This review will provide an update on the role of EUS FNA as a diagnostic tool, as well as a source of genetic material which can be used both for molecular analysis and for the creation of valuable preclinical disease models. We will also consider relevant clinical applications of EUS FNA in the management of PC, and the path towards bringing precision medicine closer to the clinic in this challenging disease.

Citing Articles

Advances in Endoscopic Ultrasound in Pancreatic Cancer Screening, Diagnosis, and Palliative Care.

Zhang W, Chen J, Zhang W, Xu M Biomedicines. 2025; 13(1).

PMID: 39857661 PMC: 11762820. DOI: 10.3390/biomedicines13010076.

The factors that influence the diagnostic accuracy and sample adequacy of EUS-guided tissue acquisition for the diagnosis of solid pancreatic lesions.

Sun L, Li Y, Song Q, Peng L, Xing Y, Huang H Endosc Ultrasound. 2024; 13(3):183-189.

PMID: 39318648 PMC: 11419504. DOI: 10.1097/eus.0000000000000060.

Molecular Characterization and Xenotransplantation of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA).

Antonova L, Paramanthan P, Falls T, Wedge M, Mayer J, Sekhon H Cancers (Basel). 2024; 16(15).

PMID: 39123450 PMC: 11311391. DOI: 10.3390/cancers16152721.

Preclinical models derived from endoscopic ultrasound-guided tissue acquisition for individualized treatment of pancreatic ductal adenocarcinoma.

Tong T, Zhang C, Li J, Deng M, Wang X Front Med (Lausanne). 2023; 9:934974.

PMID: 36687406 PMC: 9849774. DOI: 10.3389/fmed.2022.934974.

Comparison of Endoscopic Ultrasound-Guided Fine Needle Aspiration with 19-Gauge and 22-Gauge Needles for Solid Pancreatic Lesions.

Li C, Mi J, Gao F, Zhu X, Su M, Xie X Int J Gen Med. 2022; 14:10439-10446.

PMID: 35002300 PMC: 8722532. DOI: 10.2147/IJGM.S342525.

References

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A . Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008; 14(20):6456-68. DOI: 10.1158/1078-0432.CCR-08-0138. View

Garajova I, Giovannetti E, Biasco G, Peters G . c-Met as a Target for Personalized Therapy. Transl Oncogenomics. 2015; 7(Suppl 1):13-31. PMC: 4659440. DOI: 10.4137/TOG.S30534. View

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

Neuzillet C, Couvelard A, Tijeras-Raballand A, de Mestier L, de Gramont A, Bedossa P . High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015; 67(5):664-76. DOI: 10.1111/his.12691. View

Kim E, Sahai V, Abel E, Griffith K, Greenson J, Takebe N . Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014; 20(23):5937-5945. PMC: 4254161. DOI: 10.1158/1078-0432.CCR-14-1269. View

Cascinu S, Jelic S . Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4:37-40. DOI: 10.1093/annonc/mdp123. View

Borazanci E, Dang C, Robey R, Bates S, Chabot J, Von Hoff D . Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". Clin Cancer Res. 2017; 23(7):1629-1637. DOI: 10.1158/1078-0432.CCR-16-2070. View

Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S . Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006; 66(7):3928-35. DOI: 10.1158/0008-5472.CAN-05-4203. View

Villarroel M, Rajeshkumar N, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A . Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2010; 10(1):3-8. PMC: 3307340. DOI: 10.1158/1535-7163.MCT-10-0893. View

10.

Maluf-Filho F, Kumar A, Gerhardt R, Kubrusly M, Sakai P, Hondo F . Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol. 2007; 41(10):906-10. DOI: 10.1097/MCG.0b013e31805905e9. View

11.

Chang D, Grimmond S, Biankin A . Pancreatic cancer genomics. Curr Opin Genet Dev. 2014; 24:74-81. DOI: 10.1016/j.gde.2013.12.001. View

12.

Shultz L, Brehm M, Garcia-Martinez J, Greiner D . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11):786-98. PMC: 3749872. DOI: 10.1038/nri3311. View

13.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C . An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006; 12(15):4652-61. DOI: 10.1158/1078-0432.CCR-06-0113. View

14.

Bournet B, Souque A, Senesse P, Assenat E, Barthet M, Lesavre N . Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy. 2009; 41(6):552-7. DOI: 10.1055/s-0029-1214717. View

15.

Willems S, van Deurzen C, van Diest P . Diagnosis of breast lesions: fine-needle aspiration cytology or core needle biopsy? A review. J Clin Pathol. 2011; 65(4):287-92. DOI: 10.1136/jclinpath-2011-200410. View

16.

Haas M, Ormanns S, Baechmann S, Remold A, Kruger S, Westphalen C . Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Br J Cancer. 2017; 116(11):1462-1469. PMC: 5520094. DOI: 10.1038/bjc.2017.115. View

17.

van der Waaij L, van Dullemen H, Porte R . Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc. 2005; 62(3):383-9. DOI: 10.1016/s0016-5107(05)01581-6. View

18.

Witkiewicz A, Borja N, Franco J, Brody J, Yeo C, Mansour J . Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget. 2015; 6(18):15788-801. PMC: 4599237. DOI: 10.18632/oncotarget.3819. View

19.

Yamada R, Mizuno S, Uchida K, Yoneda M, Kanayama K, Inoue H . Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma.... Pancreas. 2016; 45(5):761-71. PMC: 4839740. DOI: 10.1097/MPA.0000000000000597. View

20.

Kim S, Lee J, Park S, Park J, Park Y, Kang W . Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer. 2017; 17(1):211. PMC: 5363054. DOI: 10.1186/s12885-017-3196-6. View